Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose.~2. Have plaque type psoriasis covering at least 15% of total BSA at Day 1 (at the time of the first study dose).~3. Have a PASI score of 12 or greater at Day 1 (at the time of the first study dose).~4. Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment).~Exclusion Criteria:~1. Currently have non plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis.~2. 3. Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.~3. Have received any of the following treatment regimens specified in the timeframes outlined below:~Within 9 months of first dose of study drug:~• Ustekinumab (Stelara).~Within 12 weeks of first dose of study drug:~• Any experimental therapy for psoriasis or rheumatoid arthritis.~Within 4 8 weeks of first dose of study drug:~* Biologic therapies for psoriasis have discontinuation periods determined from approximately 5x half life of the respective biologic:~* 4 weeks: etanercept (Enbrel).~* 8 weeks: infliximab (Remicade), adalimumab (Humira).~Within 4 weeks of first dose of study drug:~* Systemic treatments other than biologics that could affect psoriasis (eg, oral or injectable corticosteroids, retinoids, methotrexate, cyclosporine, fumaric acid derivatives, sulfasalazine, hydroxycarbamide (hydroxyurea), azathioprine).~* Phototherapy and psoralen plus ultraviolet A therapy (PUVA).~* Other - intramuscular gold, immunization with any live virus vaccination (eg, FluMist), herbal medications.~Within 2 weeks of first dose of study drug:~* Topical treatments that could affect psoriasis (eg, corticosteroids, tars, keratolytics, anthralin, vitamin D analogs, and retinoids).~* Phototherapy with ultraviolet B (UVB) (narrowband or broadband).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 200mg of PF-04965842 twice daily
- Cohort 2 (Type: EXPERIMENTAL): 400mg of PF-04965842 once daily
- Cohort 3 (Type: EXPERIMENTAL): 200mg of PF-04965842 once daily
- Cohort 4 (Type: PLACEBO_COMPARATOR): Placebo comparator daily

Based on this trial design, predict the completion outcome and termination type (if applicable).